130
Views
0
CrossRef citations to date
0
Altmetric
Letters to the Editor

Results from a phase I study of continuous infusion cladribine, high-dose cytarabine, and mitoxantrone for relapsed/refractory high-grade myeloid neoplasms

, , , , , , , , ORCID Icon, , , , & ORCID Icon show all
Pages 1057-1059 | Received 04 Jan 2023, Accepted 20 Feb 2023, Published online: 09 Mar 2023
 

Disclosure statement

No potential conflict of interest was reported by the author(s).

Additional information

Funding

This work was supported by the University of Washington/Fred Hutch Cancer Consortium grant NCI 5 P30 CA015704-47. Additional funding was provided to NEK through the NHLBI T32 training grant (T32 HL007093).

Log in via your institution

Log in to Taylor & Francis Online

PDF download + Online access

  • 48 hours access to article PDF & online version
  • Article PDF can be downloaded
  • Article PDF can be printed
USD 65.00 Add to cart

Issue Purchase

  • 30 days online access to complete issue
  • Article PDFs can be downloaded
  • Article PDFs can be printed
USD 1,065.00 Add to cart

* Local tax will be added as applicable

Related Research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.